{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:54Z","timestamp":1792936674766,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.semarthrit.2010.04.003","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T04:37:55Z","timestamp":1277959075000},"page":"233-240","source":"Crossref","is-referenced-by-count":228,"title":["Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis"],"prefix":"10.1016","volume":"40","author":[{"given":"Angelique N.","family":"Collamer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Battafarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl III","key":"10.1016\/j.semarthrit.2010.04.003_bib1","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2007.081430","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.sder.2006.12.002","article-title":"Complications and adverse reactions in the use of newer biologic agents","volume":"26","author":"Callen","year":"2007","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.det.2007.01.010","article-title":"Potential complications associated with the use of biologic agents for psoriasis","volume":"25","author":"Zeichner","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib4","first-page":"854","article-title":"Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience","volume":"33","author":"Moreland","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor-\u03b1 therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib9","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib10","first-page":"405","article-title":"Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports","volume":"63","author":"Haibel","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib11","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.20155","article-title":"Skin reaction to adalimumab","volume":"50","author":"Beuthien","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib12","first-page":"276","article-title":"New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-alpha antagonists: report of 8 cases","volume":"63","author":"Kary","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induced by infliximab","volume":"38","author":"Verea","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib14","first-page":"439","article-title":"Pustular psoriasis induced by infliximab","volume":"3","author":"Thurber","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by anti-tumor necrosis factor alpha treatment: two cases","volume":"150","author":"Dereure","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.20954","article-title":"Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. [letter]","volume":"52","author":"Grinblat","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib18","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sifkakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2230.2005.01882.x","article-title":"Onset of flexural psoriasis during infliximab treatment for Crohn's disease","volume":"30","author":"Peramiquel","year":"2005","journal-title":"Clin Exp Derm"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","article-title":"Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor alpha in the normal palmar eccrine sweat duct?","volume":"153","author":"Michaelsson","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00296-004-0567-5","article-title":"Pustular skin lesions in patients treated with infliximab: report of two cases","volume":"25","author":"Starmans-Kool","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib22","first-page":"1195","article-title":"Pustulose palmaire et plantaire chez une patiente traite\u2032e par adalimumab [abstract]","volume":"72","author":"Zarnitsky","year":"2005","journal-title":"Rev Rhum"},{"issue":"Suppl III","key":"10.1016\/j.semarthrit.2010.04.003_bib23","first-page":"458","article-title":"Cutaneous modifications during anti-TNF therapy in rheumatoid arthritis [abstract]","volume":"64","author":"Solau-Gervais","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib24","first-page":"1183","article-title":"Psoriasis cutan\u00e9 induit par traitement anti-TNF alpha au cours d'une fasciite \u00e9osinophile [abstract]","volume":"72","author":"Djeanne","year":"2005","journal-title":"Rev Rhum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0025-7753(06)72243-6","article-title":"Psoriasis inducida por infliximab: un hecho parad\u00f3jico [letter]","volume":"127","author":"Gonz\u00e1lez-L\u00f3pez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2006.059261","article-title":"A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents","volume":"65","author":"Ritchlin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/ard.2005.040576","article-title":"Development of new-onset psoriasis while on anti-TNF alpha treatment","volume":"65","author":"Matthews","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.rhu.0000240045.16855.39","article-title":"The appearance of pustular psoriasis during antitumor necrosis factor therapy","volume":"12","author":"Goncalves","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib29","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2005.049916","article-title":"Psoriasis after treatment of juvenile idiopathic arthritis with etanercept","volume":"65","author":"Peek","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib31","first-page":"1411","article-title":"Anti-tumor necrosis factor alpha-induced psoriasis","volume":"33","author":"Sari","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib32","first-page":"178","article-title":"Infliximab associated new-onset psoriasis","volume":"5","author":"Adams","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000095033","article-title":"Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview","volume":"213","author":"Pirard","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00296-006-0144-1","article-title":"Psoriasis onset during infliximab treatment: description of two cases","volume":"26","author":"Volpe","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kei221","article-title":"In SAPHO syndrome anti-TNF-\u03b1 therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations","volume":"45","author":"Massara","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib36","first-page":"316","article-title":"Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy","volume":"16","author":"Cassano","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","article-title":"Psoriasiform and pustular eruption induced by infliximab","volume":"34","author":"Takahashi","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0151-9638(07)89192-7","article-title":"Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab","volume":"134","author":"Cavailhes","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2230.2006.02315.x","article-title":"Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers","volume":"32","author":"Goiriz","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side effects in patients with rheumatoid diseases during application of tumor necrosis factor alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib42","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/ibd.20137","article-title":"Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist","volume":"13","author":"Angelucci","year":"2007","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.eye.6702262","article-title":"Adverse skin reactions to infliximab in the treatment of intraocular inflammation","volume":"21","author":"Wegscheider","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib45","first-page":"434","article-title":"New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?","volume":"34","author":"Roux","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib46","first-page":"438","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archderm.143.2.270","article-title":"Onset of psoriasis during treatment with TNF-\u03b1 antagonists: a report of 3 cases","volume":"143","author":"Ubriani","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib48","first-page":"231","article-title":"Cutaneous reaction to infliximab: report of psoriasis developing in 3 patients","volume":"80","author":"Severs","year":"2007","journal-title":"Cutis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000107622","article-title":"Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy","volume":"215","author":"Passarini","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archderm.143.11.1449-a","article-title":"Infliximab-induced palmoplantar pustulosis in a patient with Crohn disease","volume":"143","author":"Sladden","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib51","first-page":"1424","article-title":"Pustular psoriasis induced by infliximab","volume":"21","author":"Mart\u00ednez-Mor\u00e1n","year":"2007","journal-title":"JEADV"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0151-9638(07)89187-3","article-title":"Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases","volume":"134","author":"Lebas","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib53","first-page":"328","article-title":"Psoriasi suberitrodermica diffusa indotta da infliximab [Diffused suberitrodermic psoriasis induced by infliximab]","volume":"59","author":"Bruzzese","year":"2007","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib54","first-page":"659","article-title":"Severe bout of cutaneous psoriasis in a patient with psoriasic arthritis undergoing treatment with infliximab","volume":"25","author":"Uriarte Itzazelaia","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib55","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/ibd.20150","article-title":"Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease","volume":"13","author":"Umeno","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2340\/00015555-0425","article-title":"Induction of pustular lesions during infliximab therapy for Crohn's disease","volume":"88","author":"P\u00e9rez-P\u00e9rez","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2710.2008.00915.x","article-title":"Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab","volume":"33","author":"Borr\u00e1s-Blasco","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00105-007-1451-5","article-title":"First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept","volume":"59","author":"Boms","year":"2008","journal-title":"Hautarzt"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10067-007-0789-5","article-title":"Tumor necrosis factor-\u03b1 antagonist induced psoriasis: yet another paradox in medicine","volume":"27","author":"Aslanidis","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00403-008-0831-8","article-title":"Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on 5 cases","volume":"300","author":"M\u00f6ssner","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib61","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1468-3083.2007.02335.x","article-title":"Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-\u03b1 therapy: a case series of four patients and guidelines for management","volume":"22","author":"Papadavid","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D33D29C129","article-title":"Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis","volume":"14","author":"Chan","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D31ZH0D26Q","article-title":"A case of infliximab-induced psoriasis","volume":"14","author":"Richetta","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib64","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ibd.20450","article-title":"Guttate psoriasis induced by infliximab in a child with Crohn's disease","volume":"14","author":"Costa-Romero","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/RHU.0b013e318190dd88","article-title":"Biologic therapy (TNF-\u03b1 antagonists)-induced psoriasis","volume":"14","author":"Cuchacovich","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2007.06.011","article-title":"Onset or exacerbation of cutaneous psoriasis during TNF\u03b1 antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/RHU.0b013e31816b95bc","article-title":"Psoriasis induced by anti-TNF probably not so uncommon","volume":"14","author":"Bosch","year":"2008","journal-title":"J Clinical Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0b013e31816b95d4","article-title":"Onset of psoriasis induced by infliximab","volume":"14","author":"Bal","year":"2008","journal-title":"J Clin Rheumatol"},{"issue":"Suppl","key":"10.1016\/j.semarthrit.2010.04.003_bib70","first-page":"S781","article-title":"Is psoriasis a complication of anti-TNF treatment?","volume":"58","author":"P\u00e9rez-Zafrilla","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib71","first-page":"975","article-title":"Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors","volume":"7","author":"Egnatios","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib72","first-page":"1","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"4","author":"Exarchous","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1468-3083.2008.02898.x","article-title":"Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab","volume":"23","author":"Bordel-G\u00f3mez","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2310\/7750.2008.07080","article-title":"Occurrence of plantar pustular psoriasis during treatment with infliximab","volume":"13","author":"English","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.gastrohep.2008.09.022","article-title":"Psoriasis pustulosa inducida por infliximab en una paciente con enfermedad de Crohn [Infliximab-induced pustular psoriasis in a patient with Crohn's disease]","volume":"32","author":"Monteagudo S\u00e1nchez","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib76","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ajg.2008.101","article-title":"First case report of adalimumab-induced psoriasis in Crohn's disease","volume":"104","author":"Harris","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib77","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1016\/j.cgh.2008.08.009","article-title":"Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis","volume":"7","author":"Wermuth","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.anpedi.2008.11.013","article-title":"Psoriasis secundaria al tratamiento con infliximab y adalimumab en la enfermedad de Crohn [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease]","volume":"70","author":"Avila Alvarez","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib80","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ibd.20954","article-title":"Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers","volume":"16","author":"El Shabrawi-Caelen","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib82","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib83","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.22489","article-title":"Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options","volume":"56","author":"Turkiewicz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib84","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib85","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon-\u03b1\/\u03b2-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib86","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib87","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib88","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard.2003.008599","article-title":"Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis","volume":"63","author":"Nissinen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib89","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib90","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib91","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.0022-202X.2005.23864.x","article-title":"Increased sensitivity to interferon-\u03b1 in psoriatic T cells","volume":"125","author":"Eriksen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib92","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psorasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib93","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","article-title":"Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-\u03b1 inhibitors","volume":"44","author":"Aeberli","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib94","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K","article-title":"Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis","volume":"42","author":"Maurice","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780242","article-title":"Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris","volume":"81","author":"Rottman","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib96","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/ar2746","article-title":"Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab","volume":"11","author":"Richez","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib97","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02113.x","article-title":"Palmoplantar pustulosis: a clinical and immunohistological study","volume":"138","author":"Eriksson","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib98","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2310\/7750.2008.07036","article-title":"Long-term management of generalized pustular psoriasis with infliximab: case series","volume":"12","author":"Routhouska","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib99","first-page":"247","article-title":"Tumor necrosis factor-\u03b1 inhibition and palmoplantar pustulosis: Janus-faced therapy?","volume":"34","author":"Dutz","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib100","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib101","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2007.080929","article-title":"Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma","volume":"67","author":"Mielke","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/09546630701691236","article-title":"Efalizumab-induced guttate psoriasis","volume":"19","author":"Balato","year":"2008","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib103","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-5945-7-2","article-title":"Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series","volume":"7","author":"Lowes","year":"2007","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib104","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/archderm.143.7.900","article-title":"Efalizumab-associated papular psoriasis","volume":"143","author":"Hassan","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2310\/7750.2008.07087","article-title":"Exacerbation of psoriasis under efalizumab therapy","volume":"13","author":"Rallis","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib106","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1365-2133.2008.08470.x","article-title":"New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra","volume":"158","author":"Gonz\u00e1lez-L\u00f3pez","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib107","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00296-008-0552-5","article-title":"Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?","volume":"28","author":"Ongaro","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib108","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.genom.6.080604.162324","article-title":"The genetics of psoriasis and autoimmunity","volume":"6","author":"Bowcock","year":"2005","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.semarthrit.2010.04.003_bib109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/jid.2008.297","article-title":"Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22","volume":"129","author":"Li","year":"2009","journal-title":"J Invest Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T07:42:20Z","timestamp":1740210140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017210000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0049017210000739"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2010.04.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}